新兴传染病疫苗：中东呼吸综合征冠状病毒和寨卡病毒带来的启示。
Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus.
机构信息
a GeneOne Life Science, Inc. Seoul , Korea.
出版信息
Hum Vaccin Immunother. 2017 Dec 2;13(12):2918-2930. doi: 10.1080/21645515.2017.1358325. Epub 2017 Aug 28.
Abstract
The past decade and a half has been characterized by numerous emerging infectious diseases. With each new threat, there has been a call for rapid vaccine development. Pathogens such as the Middle East Respiratory Syndrome coronavirus (MERS-CoV) and the Zika virus represent either new viral entities or viruses emergent in new geographic locales and characterized by novel complications. Both serve as paradigms for the global spread that can accompany new pathogens. In this paper, we review the epidemiology and pathogenesis of MERS-CoV and Zika virus with respect to vaccine development. The challenges in vaccine development and the approach to clinical trial design to test vaccine candidates for disease entities with a changing epidemiology are discussed.
摘要
过去十五年的时间里出现了许多新发传染病。每出现一种新的威胁，就会有人呼吁快速开发疫苗。中东呼吸综合征冠状病毒（MERS-CoV）和寨卡病毒等病原体要么是新的病毒实体，要么是在新的地理区域出现的新型病毒，并具有新的并发症。两者都可作为伴随新病原体出现的全球传播的范例。在本文中，我们将回顾 MERS-CoV 和寨卡病毒的流行病学和发病机制，以及它们在疫苗开发方面的情况。讨论了疫苗开发所面临的挑战，以及针对具有不断变化的流行病学的疾病实体测试疫苗候选物的临床试验设计方法。
相似文献
1
Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus.新兴传染病疫苗：中东呼吸综合征冠状病毒和寨卡病毒带来的启示。
Hum Vaccin Immunother. 2017 Dec 2;13(12):2918-2930. doi: 10.1080/21645515.2017.1358325. Epub 2017 Aug 28.
2
Vaccine development for emerging virulent infectious diseases.针对新出现的烈性传染病的疫苗研发。
Vaccine. 2017 Oct 4;35(41):5437-5443. doi: 10.1016/j.vaccine.2017.02.015. Epub 2017 Feb 16.
3
Receptor-binding domain-based subunit vaccines against MERS-CoV.基于受体结合域的中东呼吸综合征冠状病毒亚单位疫苗。
Virus Res. 2015 Apr 16;202:151-9. doi: 10.1016/j.virusres.2014.11.013. Epub 2014 Nov 20.
4
Vaccines for the prevention against the threat of MERS-CoV.用于预防中东呼吸综合征冠状病毒威胁的疫苗。
Expert Rev Vaccines. 2016 Sep;15(9):1123-34. doi: 10.1586/14760584.2016.1167603. Epub 2016 Apr 6.
5
A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.一种基于重组麻疹病毒疫苗平台的高免疫原性和保护性中东呼吸综合征冠状病毒疫苗。
J Virol. 2015 Nov;89(22):11654-67. doi: 10.1128/JVI.01815-15. Epub 2015 Sep 9.
6
Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus.快速应对新发传染病——针对寨卡病毒的合成 DNA 疫苗开发的经验教训。
Microbes Infect. 2018 Dec;20(11-12):676-684. doi: 10.1016/j.micinf.2018.03.001. Epub 2018 Mar 17.
7
Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.中东呼吸综合征冠状病毒疫苗的研发——进展与挑战。
Hum Vaccin Immunother. 2018 Feb 1;14(2):304-313. doi: 10.1080/21645515.2017.1389362. Epub 2017 Nov 29.
8
Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches.中东呼吸综合征冠状病毒疫苗：现状与新方法
Curr Opin Virol. 2017 Apr;23:49-58. doi: 10.1016/j.coviro.2017.03.007. Epub 2017 Apr 13.
9
Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development.新兴传染病实验室和诊断准备工作以加速疫苗开发。
Hum Vaccin Immunother. 2019;15(10):2258-2263. doi: 10.1080/21645515.2019.1634992. Epub 2019 Jul 16.
10
Zika Virus Vaccine Development: Progress in the Face of New Challenges.寨卡病毒疫苗的开发：新挑战面前的进展。
Annu Rev Med. 2019 Jan 27;70:121-135. doi: 10.1146/annurev-med-040717-051127. Epub 2018 Nov 2.
引用本文的文献
1
A novel approach to designing viral precision vaccines applied to SARS-CoV-2.一种设计针对 SARS-CoV-2 的病毒精准疫苗的新方法。
Front Cell Infect Microbiol. 2024 Apr 2;14:1346349. doi: 10.3389/fcimb.2024.1346349. eCollection 2024.
2
Application of Traditional Vaccine Development Strategies to SARS-CoV-2.传统疫苗开发策略在 SARS-CoV-2 中的应用。
mSystems. 2023 Apr 27;8(2):e0092722. doi: 10.1128/msystems.00927-22. Epub 2023 Mar 2.
3
Application of Traditional Vaccine Development Strategies to SARS-CoV-2.传统疫苗研发策略在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）上的应用
ArXiv. 2023 Jan 23:arXiv:2208.08907v2.
4
Keeping up with the COVID's-Could siRNA-based antivirals be a part of the answer?紧跟新冠疫情——基于小干扰RNA的抗病毒药物会是解决方案的一部分吗？
Exploration (Beijing). 2022 Jul 14;2(6):20220012. doi: 10.1002/EXP.20220012.
5
Planetary health & COVID-19: A multi-perspective investigation.行星健康与新冠疫情：多视角调查
One Health. 2022 Dec;15:100416. doi: 10.1016/j.onehlt.2022.100416. Epub 2022 Jul 22.
6
Co-administration of a plasmid encoding CD40 or CD63 enhances the immune responses to a DNA vaccine against bovine viral diarrhea virus in mice.共给药编码 CD40 或 CD63 的质粒可增强针对牛病毒性腹泻病毒的 DNA 疫苗在小鼠体内的免疫应答。
J Vet Med Sci. 2022 Sep 1;84(9):1175-1184. doi: 10.1292/jvms.22-0085. Epub 2022 Jul 7.
7
Recent Update of COVID-19 Vaccines.新型冠状病毒肺炎疫苗的最新情况
Adv Pharm Bull. 2022 Mar;12(2):219-236. doi: 10.34172/apb.2022.045. Epub 2021 Oct 4.
8
COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review.COVID-19四期候选疫苗、对SARS-CoV-2变体的有效性、中和抗体、罕见副作用、传统和基于纳米的疫苗平台：综述
3 Biotech. 2022 Jan;12(1):15. doi: 10.1007/s13205-021-03076-0. Epub 2021 Dec 12.
9
SARS-CoV-2 vaccination in patients with inflammatory bowel disease.炎症性肠病患者接种新型冠状病毒2型疫苗
GastroHep. 2021 Jul;3(4):212-228. doi: 10.1002/ygh2.473. Epub 2021 Jul 23.
10
Vaccine against SARS-CoV-2: Challenges and considerations.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的疫苗：挑战与考量
Can Commun Dis Rep. 2021 Mar 31;47(3):128-131. doi: 10.14745/ccdr.v47i03a01.
本文引用的文献
1
protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine.通过被动抗体转移和使用prMEnv DNA疫苗进行主动免疫来预防寨卡病毒感染和发病机制。
NPJ Vaccines. 2016 Nov 10;1:16021. doi: 10.1038/npjvaccines.2016.21. eCollection 2016.
2
Maternal Zika Virus Disease Severity, Virus Load, Prior Dengue Antibodies, and Their Relationship to Birth Outcomes.孕妇寨卡病毒病的严重程度、病毒载量、既往登革热抗体及其与分娩结局的关系。
Clin Infect Dis. 2017 Sep 15;65(6):877-883. doi: 10.1093/cid/cix472.
3
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.巴西和墨西哥出现的针对寨卡病毒的复发性强效人类中和抗体
Cell. 2017 May 4;169(4):597-609.e11. doi: 10.1016/j.cell.2017.04.024.
4
Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys.寨卡病毒在恒河猴中枢神经系统和淋巴结中的持续存在
Cell. 2017 May 4;169(4):610-620.e14. doi: 10.1016/j.cell.2017.04.008. Epub 2017 Apr 27.
5
Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection.登革病毒感染不会产生针对寨卡病毒的持久交叉中和抗体。
Emerg Infect Dis. 2017 May;23(5):773-781. doi: 10.3201/eid2305.161630.
6
Zika Virus Infection and Associated Neurologic Disorders in Brazil.巴西的寨卡病毒感染及相关神经系统疾病
N Engl J Med. 2017 Apr 20;376(16):1591-1593. doi: 10.1056/NEJMc1608612. Epub 2017 Mar 29.
7
A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models.一种寨卡病毒减毒活疫苗候选株在小鼠模型中诱导了绝育免疫。
Nat Med. 2017 Jun;23(6):763-767. doi: 10.1038/nm.4322. Epub 2017 Apr 10.
8
Viral and serological kinetics in Zika virus-infected patients in South Korea.韩国寨卡病毒感染患者的病毒学和血清学动力学
Virol J. 2017 Apr 7;14(1):70. doi: 10.1186/s12985-017-0740-6.
9
Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity.既往抗黄病毒免疫增强寨卡病毒致病性
Science. 2017 Apr 14;356(6334):175-180. doi: 10.1126/science.aal4365. Epub 2017 Mar 30.
10
Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.基于刺突蛋白的 MERS-CoV 候选 DNA 疫苗的免疫原性。
Sci Rep. 2017 Mar 23;7:44875. doi: 10.1038/srep44875.
Zotero 插件